Court Rules Against Sanofi In Lovenox Patent Case Again; Second Round Of Appeals Likely
This article was originally published in The Pink Sheet Daily
Executive Summary
Denial of a second appeal of a U.S. District Court’s decision that Teva and Amphastar are not infringing the Lovenox patent could open door to generic launches.
You may also be interested in...
Sanofi Loses Another Lovenox Round
“All options” under review in legal battle against generics.
Sanofi Loses Another Lovenox Round
“All options” under review in legal battle against generics.
Sanofi Vaccine Sales Jump 50 Percent In Q3
Performance of vaccines business helps offset slight decline in pharmaceuticals revenues, hard hit by Ambien IR generics.